OncoHost Wins 2026 BIG Innovation Award for AI-driven oncology platform

Original source here

OncoHost has been honored with the 2026 BIG Innovation Award in the Health category and named a Top 10 Small Business Innovator for its PROphet platform, an AI-powered plasma-proteomics solution that aids oncologists in personalized treatment decisions for NSCLC.

‍

OncoHost announced today that it has been named a winner in the 2026 BIG Innovation Awards in the Health category. In addition, OncoHost has been selected as a Top 10 Innovator – Small Business.

Presented by the Business Intelligence Group, the BIG Innovation Awards is a global recognition program honoring organizations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.

OncoHost was recognized for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumor-only biomarkers.

PROphet analyzes over 7,000 circulating proteins per patient and applies proprietary machine learning models to generate individualized predictive scores—supporting more confident, evidence-based decisions and helping physicians choose the optimal treatment path from day one.

In the past year, OncoHost has continued to strengthen PROphet’s biological explainability and clinical relevance, including a JITC-published study decoding resistance mechanisms in NSCLC, while accelerating adoption and expanding global collaborations across precision oncology.

‍